Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Completed · Phase 2

Conditions studied: Breast Cancer, Breast Neoplasm

In brief

The purpose of this study is to evaluate the clinical benefit rate at 12 weeks from the addition of pazopanib to a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) in patients with hormone receptor positive advanced breast cancer progressing on the same NSAI hormone therapy.

Key facts

Study ID

NCT01466972

Run by

Hope Rugo, MD

People needed

30

Starts

2012-04-27

Expected to finish

2019-10-02

Last updated by the study team

2020-07-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up.
• Procedures conducted as a part of routine clinical management of the subject (e.g., blood count, imaging study) and obtained prior to signed informed consent may be utilized for Screening or Baseline purposes provided these tests are obtained as specified in the protocol).
• Subjects must have measurable or evaluable disease. Disease sites that are evaluable for progression but not measurable per RECIST guidelines include:
• Bone lesions
• Previously irradiated lesions
• Cutaneous manifestations (non-discreet lesions only)
• Age ≥ 18 years.
• Postmenopausal women defined by one of the criteria:
• No spontaneous menses for at least 12 months if the subject is ≥ 50 years old;
• Amenorrheic for at least 12 months if the subject is < 50 years old, with serum estradiol within the institutional postmenopausal range;
• Bilateral oophorectomy;
• If prior hysterectomy but intact ovaries, must be ≥ 55 years old, or have serum estradiol within the postmenopausal range;
• If premenopausal, must be on a GnRH agonist (leuprolide or goserelin) with serum estradiol levels within the institutional postmenopausal range.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
• Histologically or cytologically confirmed estrogen receptor (ER) and/or progesterone receptor (PgR) positive carcinoma of the breast with unresectable, locally advanced and/or metastatic (AJCC Stage IV) disease.
• Subjects must have received prior hormonal therapy for the treatment of breast cancer as follows:
• Progression must be documented while taking a nonsteroidal aromatase inhibitor including anastrozole or letrozole.
• No more than 2 prior hormonal therapies for metastatic disease.
• If hormonal therapy was administered in the adjuvant setting, subjects must have received therapy for at least 6 months prior to developing metastatic disease.
• Note: A regimen of sequential tamoxifen/AI in the adjuvant setting is considered to be one therapy
• If hormonal therapy was administered in the metastatic setting, subjects must have received therapy for at least 3 months prior to progression
• Subjects whose tumors overexpress ErbB2 are eligible provided that they have progressed following therapy which included trastuzumab and/or lapatinib.
• Note for prior lapatinib: Subjects must have completed therapy with lapatinib at least 7 days prior to the first dose of study drug.
• Note for prior trastuzumab: Subjects who received Q3 weekly, Q2 weekly or Q1 weekly must have completed therapy with trastuzumab at least 3 weeks, 2 weeks or 1 week, respectively, prior to the first dose of study drug.
• Adequate hematologic and hepatic function as defined in Protocol Table 1

You may not qualify if…

• Prior use of pazopanib
• Premenopausal levels of estradiol, or ongoing menses (see definitions of menopause above).
• Known central nervous system (CNS) metastases or leptomeningeal carcinomatosis. Screening with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if the subject has clinical findings suggestive of CNS metastasis.
• History of another active malignancy. Note: Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.
• Clinically significant gastrointestinal abnormalities which might interfere with oral dosing, including, but not limited to:
• Malabsorption syndrome
• Major resection of the stomach or small bowel that could affect the absorption of study drug
• Inflammatory bowel disease
• Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation
• History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment
• Presence of uncontrolled infection.
• Prolongation of corrected QT interval (QTc) >480msecs.
• History of any one or more of the following cardiovascular conditions within the past 6 months:
• Angioplasty or stenting
• Myocardial infarction
• Unstable angina
• Coronary artery by-pass graft surgery
• Symptomatic peripheral vascular disease
• Class II, III or IV congestive heart failure, as defined by the New York Heart Association (NYHA).
• Use of an investigational agent, including an investigational anti-cancer agent, within 14 days prior to the first dose of study drug.
• Prior use of an investigational drug that targets VEGF or VEGF receptors.
• Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity.
• Poorly controlled hypertension (defined as systolic blood pressure (SBP) of ≥140mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg).
• Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Blood pressure must be re-assessed prior to start of study therapy. The mean SBP/DBP values must be <140/90mmHg (OR 150/90mmHg, if this criterion is approved by Safety Review Team) in order for a subject to be eligible for the study.
• History of cerebrovascular accident (CVA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.